Latest Antivirals Stories
“Letermovir keeps the…Cytomegalovirus in check for weakened immune systems of infected transplant patients,” according to an article published on MedicalXpress.com on May 8, 2014 (1).
In its latest May 2014 survey, polyDNA found that 68% of respondents did not know if the same antiviral treatments are used against genital and oral herpes infections.
polyDNA’s newest survey for the month of May discovered that 36% of respondents with arthritis wanted to know if EBV is the cause of their disease.
polyDNA’s April 2014 survey found that 24% of respondents wanted to know if a common virus can cause brain cancer.
WUPPERTAL, Germany and WHITEHOUSE STATION, New Jersey, May 8, 2014 /PRNewswire/ -- AiCuris and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today
- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date1 NORTH CHICAGO, Ill., May 8, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV)
-- Filing Includes Data from Treatment-Naive Patients with Advanced Fibrosis and Null Responders with All Stages of Liver Fibrosis -- RARITAN, N.J., May 7, 2014 /PRNewswire/ -- Janssen Research
ROCKLAND, Mass., April 25, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio
Indiana Fiber Network (IFN), the leading Indiana statewide Network Service Provider, announced the appointment of a new executive to its leadership team: Ron Galle as the company's Chief Financial
-Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date(1) NORTH CHICAGO, Ill., April 22, 2014 /PRNewswire/ -- AbbVie (NYSE:
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.